Case Study: Sanofi achieves global adoption of Beyfortus with IDEO's newborn RSV immunization toolkit

Sanofi launches Beyfortus with IDEO, reaching $1.8B in first-year sales

Sanofi, a global healthcare company, faced the challenge of launching Beyfortus, the world's first RSV immunization for newborns, across more than 20 markets amid widespread vaccine hesitancy. They partnered with the design firm IDEO to identify potential adoption hurdles and create a strategy to overcome them, ensuring a successful global rollout.

IDEO conducted research in key markets and designed a customizable communication toolkit to support informed conversations between healthcare providers and parents. This patient-centric approach contributed to a highly successful launch, with Beyfortus achieving $1.8 billion in first-year sales and an 85.9% reduction in hospitalizations for immunized infants. IDEO's work helped Sanofi meet its global-local strategy goals and immunize over six million babies to date.

Sanofi